#Israel #CollPlant #Rehovot #LightSolver #Ruti Ben Shlomi

Dr. Ruti Ben Shlomi Joins CollPlant's Board of Directors

CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) has recently announced the addition of Dr. Ruti Ben Shlomi to its Board of Directors. This decision comes promptly after the successful acquisition of LightSolver Ltd., a move that significantly boosts CollPlant's strategic position in the realm of photonic computing. Dr. Ruti, who co-founded LightSolver and has served as its CEO, brings a wealth of expertise in both scientific research and entrepreneurial ventures.

Vision for High-Performance Computing

Dr. Ben Shlomi's expertise in photonic computing is expected to propel CollPlant to new heights. LightSolver is at the forefront of developing a revolutionary Laser Processing Unit (LPU) that harnesses the physics of light to achieve energy-efficient computations. This technology aims to tackle demanding computational tasks across various sectors such as scientific research, engineering, and artificial intelligence.

“Welcoming Dr. Ruti Ben Shlomi to our Board is a momentous step for CollPlant,” said Yehiel Tal, Chairperson and CEO of CollPlant. “Her pioneering role in photonic computing differentiates her in the deep-tech sector, and we are excited about the innovative perspectives she will bring to our team.”

A Journey to Photonic Computing

Dr. Ben Shlomi's scientific journey is noteworthy. With over 15 years of experience in quantum, atomic, and molecular physics, she has made significant strides in the field. Her career highlights include groundbreaking research at the Weizmann Institute of Science, where she delved deep into the complexities of quantum signatures using ultra-cold atoms and ions. Prior to her entrepreneurial endeavor with LightSolver, she contributed her prowess as a process engineer at Intel Corporation.

Her academic qualifications include a Ph.D. in Quantum and Atomic/Molecular Physics from the Weizmann Institute, an M.Sc. in Physics from Ben-Gurion University, and a B.Sc. in Biophysics from Bar-Ilan University, underscoring her solid foundation in scientific inquiry.

Steps Towards Commercialization

The acquisition of LightSolver marks a pivotal expansion for CollPlant into the domain of high-performance computing. In her new role, Dr. Ben Shlomi plans to spearhead the transition of LightSolver’s innovative solutions from technology validation to commercialization. “This acquisition paves the way for establishing photonic computing as a core computing architecture for robust computational workloads,” expressed Dr. Ben Shlomi. She is eager to collaborate closely with CollPlant's board and executive team, aiming to cultivate long-term advantages for its stakeholders.

Future Prospects for CollPlant

CollPlant stands as a trailblazer in regenerative medicine and advanced computing. The integration of LightSolver's photonic technologies fosters a synergetic collaboration that could lead to groundbreaking advancements across various industries, including aerospace and defense, while still enhancing CollPlant's commitments to biotechnology innovations. Their endeavors in 3D bioprinting, tissue repair, and medical aesthetics aim to revolutionize healthcare solutions globally.

This strategic move not only enhances CollPlant’s technological portfolio but also sets a unique stage for pioneering changes in high-stakes computing challenges that many industries face today. As CollPlant continues to broaden its horizons, it promises to deliver transformative solutions across both biotechnological and tech sectors, paving the future for a new era of innovation.

In conclusion, the appointment of Dr. Ruti Ben Shlomi alongside the acquisition of LightSolver signals an exciting trajectory for CollPlant, as it aspires to lead advancements in photonic computing and redefine capabilities within the biotech sector.